Drugs / NTQ5082
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06558656 | Aug → Dec 2024 overdue | complement deficiency | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06560593 | Aug → Dec 2024 overdue | — | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06982040 | May 2025 → Sep 2026 overdue | IgA glomerulonephritis | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06764303 | Jan → Jul 2025 overdue | paroxysmal nocturnal hemoglobinuria | Nanjing Chia-tai Tianqing Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07177872 | Jun 2026 → Jun 2028 expected | paroxysmal nocturnal hemoglobinuria | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07177859 | Nov 2025 → Nov 2026 expected | paroxysmal nocturnal hemoglobinuria | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTQ5082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06764303 ↗ |
| Action | Inhibit | “NTQ5082 capsule is a small molecule CFB factor inhibitor.” NCT06558656 ↗ |
| Modality | Small molecule | “NTQ5082 capsule is a small molecule CFB factor inhibitor.” NCT06558656 ↗ |
| Route | Oral | “single oral administration of NTQ5082 capsules” NCT06558656 ↗ |
| Target | CFB | “NTQ5082 capsule is a small molecule CFB factor inhibitor.” NCT06558656 ↗ |